| A model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus–advanced fibrosis S Alonso López, ML Manzano, F Gea, ML Gutiérrez, AM Ahumada, ... Hepatology 72 (6), 1924-1934, 2020 | 64 | 2020 |
| A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis S Alonso, ML Manzano, F Gea, ML Gutiérrez, AM Ahumada, MJ Devesa, ... Hepatology, 2020 | 10 | 2020 |
| Enfermedad hepática inducida por alcohol AF Tubío, JCR Cobo, LT Villajos, R Martín-Mateos Medicine-Programa de Formación Médica Continuada Acreditado 13 (4), 182-190, 2020 | 6 | 2020 |
| Protocolo diagnóstico, terapéutico y de seguimiento del paciente con enfermedad hepática grasa no alcohólica R Sánchez-Aldehuelo, JCR Cobo, ES Rodríguez, D Burgos-Santamaría Medicine-Programa de Formación MéDica Continuada Acreditado 13 (4), 215-219, 2020 | 6 | 2020 |
| Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination J Llaneras, JC Ruiz-Cobo, A Rando-Segura, A Barreira-Díaz, ... JHEP Reports 6 (1), 100932, 2024 | 5 | 2024 |
| An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury M Riveiro‐Barciela, A Barreira‐Díaz, MT Salcedo, A Callejo‐Pérez, ... Alimentary Pharmacology & Therapeutics, 2024 | 3 | 2024 |
| Hemorragia digestiva en paciente con hiperplasia de glándulas de Brunner R Sánchez-Aldehuelo, JC Ruiz-Cobo, C Senosiain Lalastra, ... Revista colombiana de Gastroenterología 34 (4), 421-424, 2019 | 2 | 2019 |
| Assessing the rate of non‐linkage to care and identifying barriers in individuals living with hepatitis B. Results of the LINK‐B study A Feliu‐Prius, A Barreira‐Díaz, A Rando, E Vargas‐Accarino, A Palom, ... Liver International 44 (3), 706-714, 2024 | 1 | 2024 |
| A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors MR Barciela, A Barreira, MT Salcedo, A Callejo-Pérez, E Muñoz-Couselo, ... Journal of Hepatology 78, S375-S376, 2023 | 1 | 2023 |
| Estudio de la alteración de las pruebas de función hepática en el embarazo JCR Cobo, IG de la Filia, D Burgos-Santamaría, R Martín-Mateos Medicine-Programa de Formación Médica Continuada Acreditado 13 (4), 230-234, 2020 | 1 | 2020 |
| TOP-139 Combination of liver steatosis and premenopausal is a risk factor for DILI due to cyclin-dependent kinase 4/6 inhibitors as first-line treatment for metastatic breast … KS Vega-Cano, L Ruiz-Ortega, PM Baselga, P Esteban, OM Viñas, ... Journal of Hepatology 80, S702, 2024 | | 2024 |
| THU-028 Usefulness of an educational activity through an informatic tool in participants with chronic hepatitis B infection J Romero-Vico, A Feliu-Prius, E Sánchez-Gavilán, M Ribó, A Palom, ... Journal of Hepatology 80, S633, 2024 | | 2024 |
| SAT-393 Profile of miRNAs in chronic hepatitis D patients with or without viral replication MF Cortese, BP Ruiz, A Palom, S Garcia-Garcia, JP Garreta, D Tabernero, ... Journal of Hepatology 80, S746, 2024 | | 2024 |
| THU-395 Is hepatitis C screening based on risk factors enough in primary care setting? E Vargas-Accarino, A Rando-Segura, I Arcusa, E de Diego, N García, ... Journal of Hepatology 80, S822-S823, 2024 | | 2024 |
| FRI-432 The concentration of HDV-RNA correlates with the probability of developing clinical events in patients with chronic hepatitis D A Palom, S Rodriguez-Tajes, A Bono, A Madejón, A Rando-Segura, ... Journal of Hepatology 80, S787, 2024 | | 2024 |
| SAT-381 Low diversity of the TCRbeta repertoire in patients with chronic hepatitis D MF Cortese, A Palom, BP Ruiz, F Rudilla, EE Randé, MA Iborra, ... Journal of Hepatology 80, S741-S742, 2024 | | 2024 |
| Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry M Riveiro‐Barciela, A Barreira‐Díaz, P Esteban, R Rota, ... Liver International, 2024 | | 2024 |
| Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir JC Ruiz‐Cobo, J Llaneras, X Forns, A Gallego Moya, I Conde Amiel, ... Alimentary Pharmacology & Therapeutics, 2024 | | 2024 |
| Acute kidney injury and point-of-care ultrasound in liver cirrhosis: redefining hepatorenal syndrome EJ Banegas-Deras, J Mazón-Ruiz, G Romero-González, JC Ruiz-Cobo, ... Clinical Kidney Journal, sfae112, 2024 | | 2024 |
| Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination J Llaneras Artigues, JC Ruiz Cobo, A Barreira Diaz, ... Elsevier, 2024 | | 2024 |
